Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Viral Vector Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global viral vector manufacturing market reached a value of US$ 746.6 Million in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3,162.5 Million by 2027 exhibiting a growth rate (CAGR) of 25.40% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Viral Vector Manufacturing Market Trends:

The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global viral vector manufacturing market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, disease, application and end user.

Breakup by Type:

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Adenoviral Vectors
  • Adeno-associated Viral Vectors
  • Lentiviral Vectors
  • Retroviral Vectors
  • Others
     

Breakup by Disease:

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others
     

Breakup by Application:

  • Gene Therapy
  • Vaccinology
     

Breakup by End User:

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
     

Breakup by Region:

 

 
 

www.imarcgroup.com

To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Million
Segment Coverage Type, Disease, Application, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Viral Vector Manufacturing Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Type
    6.1    Adenoviral Vectors
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Adeno-associated Viral Vectors
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Lentiviral Vectors
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Retroviral Vectors
        6.4.1 Market Trends
        6.4.2 Market Forecast
    6.5    Others
        6.5.1 Market Trends
        6.5.2 Market Forecast
7    Market Breakup by Disease
    7.1    Cancer
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Genetic Disorders
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Infectious Diseases
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Others
        7.4.1 Market Trends
        7.4.2 Market Forecast
8    Market Breakup by Application
    8.1    Gene Therapy
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Vaccinology
        8.2.1 Market Trends
        8.2.2 Market Forecast
9    Market Breakup by End User
    9.1    Pharmaceutical and Biopharmaceutical Companies
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Research Institutes
        9.2.1 Market Trends
        9.2.2 Market Forecast
10    Market Breakup by Region
    10.1    North America
        10.1.1 United States
           10.1.1.1 Market Trends
           10.1.1.2 Market Forecast
        10.1.2 Canada
           10.1.2.1 Market Trends
           10.1.2.2 Market Forecast
    10.2    Asia-Pacific
        10.2.1 China
           10.2.1.1 Market Trends
           10.2.1.2 Market Forecast
        10.2.2 Japan
           10.2.2.1 Market Trends
           10.2.2.2 Market Forecast
        10.2.3 India
           10.2.3.1 Market Trends
           10.2.3.2 Market Forecast
        10.2.4 South Korea
           10.2.4.1 Market Trends
           10.2.4.2 Market Forecast
        10.2.5 Australia
           10.2.5.1 Market Trends
           10.2.5.2 Market Forecast
        10.2.6 Indonesia
           10.2.6.1 Market Trends
           10.2.6.2 Market Forecast
        10.2.7 Others
           10.2.7.1 Market Trends
           10.2.7.2 Market Forecast
    10.3    Europe
        10.3.1 Germany
           10.3.1.1 Market Trends
           10.3.1.2 Market Forecast
        10.3.2 France
           10.3.2.1 Market Trends
           10.3.2.2 Market Forecast
        10.3.3 United Kingdom
           10.3.3.1 Market Trends
           10.3.3.2 Market Forecast
        10.3.4 Italy
           10.3.4.1 Market Trends
           10.3.4.2 Market Forecast
        10.3.5 Spain
           10.3.5.1 Market Trends
           10.3.5.2 Market Forecast
        10.3.6 Russia
           10.3.6.1 Market Trends
           10.3.6.2 Market Forecast
        10.3.7 Others
           10.3.7.1 Market Trends
           10.3.7.2 Market Forecast
    10.4    Latin America
        10.4.1 Brazil
           10.4.1.1 Market Trends
           10.4.1.2 Market Forecast
        10.4.2 Mexico
           10.4.2.1 Market Trends
           10.4.2.2 Market Forecast
        10.4.3 Others
           10.4.3.1 Market Trends
           10.4.3.2 Market Forecast
    10.5    Middle East and Africa
        10.5.1 Market Trends
        10.5.2 Market Breakup by Country
        10.5.3 Market Forecast
11    SWOT Analysis
    11.1    Overview
    11.2    Strengths
    11.3    Weaknesses
    11.4    Opportunities
    11.5    Threats
12    Value Chain Analysis
13    Porters Five Forces Analysis

    13.1    Overview
    13.2    Bargaining Power of Buyers
    13.3    Bargaining Power of Suppliers
    13.4    Degree of Competition
    13.5    Threat of New Entrants
    13.6    Threat of Substitutes
14    Price Analysis
15    Competitive Landscape

    15.1    Market Structure
    15.2    Key Players
    15.3    Profiles of Key Players
        15.3.1    Cognate BioServices Inc. (Charles River Laboratories International Inc.)
           15.3.1.1 Company Overview
           15.3.1.2 Product Portfolio
        15.3.2    F. Hoffmann-La Roche AG
           15.3.2.1 Company Overview
           15.3.2.2 Product Portfolio
           15.3.2.3 Financials
        15.3.3    FinVector Oy
           15.3.3.1 Company Overview
           15.3.3.2 Product Portfolio
        15.3.4    FUJIFILM Holdings Corporation
           15.3.4.1 Company Overview
           15.3.4.2 Product Portfolio
           15.3.4.3 Financials
           15.3.4.4 SWOT Analysis
        15.3.5    Kaneka Eurogentec S.A. (Kaneka Corporation)
           15.3.5.1 Company Overview
           15.3.5.2 Product Portfolio
        15.3.6    Lonza Group AG
           15.3.6.1 Company Overview
           15.3.6.2 Product Portfolio
           15.3.6.3 Financials
           15.3.6.4 SWOT Analysis
        15.3.7    Merck KGaA
           15.3.7.1 Company Overview
           15.3.7.2 Product Portfolio
           15.3.7.3 Financials
           15.3.7.4 SWOT Analysis
        15.3.8    Oxford Biomedica plc
           15.3.8.1 Company Overview
           15.3.8.2 Product Portfolio
           15.3.8.3 Financials
           15.3.8.4 SWOT Analysis
        15.3.9    REGENXBIO Inc.
           15.3.9.1 Company Overview
           15.3.9.2 Product Portfolio
           15.3.9.3 Financials
           15.3.9.4 SWOT Analysis
        15.3.10    Sanofi S.A.
           15.3.10.1 Company Overview
           15.3.10.2 Product Portfolio
           15.3.10.3 Financials
           15.3.10.4 SWOT Analysis
        15.3.11    Thermo Fisher Scientific Inc.
           15.3.11.1 Company Overview
           15.3.11.2 Product Portfolio
           15.3.11.3 Financials
           15.3.11.4 SWOT Analysis
        15.3.12    uniQure N.V.
           15.3.12.1 Company Overview
           15.3.12.2 Product Portfolio
           15.3.12.3 Financials

List of Figures

Figure 1: Global: Viral Vector Manufacturing Market: Major Drivers and Challenges
Figure 2: Global: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016-2021
Figure 3: Global: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 4: Global: Viral Vector Manufacturing Market: Breakup by Type (in %), 2021
Figure 5: Global: Viral Vector Manufacturing Market: Breakup by Disease (in %), 2021
Figure 6: Global: Viral Vector Manufacturing Market: Breakup by Application (in %), 2021
Figure 7: Global: Viral Vector Manufacturing Market: Breakup by End User (in %), 2021
Figure 8: Global: Viral Vector Manufacturing Market: Breakup by Region (in %), 2021
Figure 9: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Viral Vector Manufacturing (Retroviral Vectors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Viral Vector Manufacturing (Retroviral Vectors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Viral Vector Manufacturing (Other Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Viral Vector Manufacturing (Other Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Viral Vector Manufacturing (Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Viral Vector Manufacturing (Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Viral Vector Manufacturing (Genetic Disorders) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Viral Vector Manufacturing (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Viral Vector Manufacturing (Infectious Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Viral Vector Manufacturing (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Viral Vector Manufacturing (Other Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Viral Vector Manufacturing (Other Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Viral Vector Manufacturing (Gene Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Viral Vector Manufacturing (Gene Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Viral Vector Manufacturing (Vaccinology) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Viral Vector Manufacturing (Vaccinology) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Viral Vector Manufacturing (Research Institutes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Viral Vector Manufacturing (Research Institutes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: North America: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: North America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: United States: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: United States: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Canada: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Canada: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Asia-Pacific: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Asia-Pacific: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: China: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: China: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Japan: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Japan: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: India: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: India: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: South Korea: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: South Korea: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Australia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Australia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Indonesia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Indonesia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Europe: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Europe: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Germany: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Germany: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: France: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: France: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: United Kingdom: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: United Kingdom: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Italy: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Italy: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Spain: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Spain: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Russia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Russia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Latin America: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Latin America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Brazil: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Brazil: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Mexico: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Mexico: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Middle East and Africa: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Middle East and Africa: Viral Vector Manufacturing Market: Breakup by Country (in %), 2021
Figure 83: Middle East and Africa: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 84: Global: Viral Vector Manufacturing Industry: SWOT Analysis
Figure 85: Global: Viral Vector Manufacturing Industry: Value Chain Analysis
Figure 86: Global: Viral Vector Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Viral Vector Manufacturing Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Viral Vector Manufacturing Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 3: Global: Viral Vector Manufacturing Market Forecast: Breakup by Disease (in Million US$), 2022-2027
Table 4: Global: Viral Vector Manufacturing Market Forecast: Breakup by Application (in Million US$), 2022-2027
Table 5: Global: Viral Vector Manufacturing Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 6: Global: Viral Vector Manufacturing Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Viral Vector Manufacturing Market: Competitive Structure
Table 8: Global: Viral Vector Manufacturing Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

The global viral vector manufacturing market was valued at US$ 746.6 Million in 2021.

 

We expect the global viral vector manufacturing market to exhibit a CAGR of 25.40% during 2022-2027.

The sudden outbreak of the COVID-19 pandemic has led to the escalating demand for viral vector vaccines manufacturing for novel drug delivery to boost the immunity against the coronavirus infection.

The increasing number of cancer patients, along with the rising adoption of viral vector manufacturing to deliver HIV-inhibiting transgenes to Human Hematopoietic Stem Cells (HSCs), is primarily driving the global viral vector manufacturing market.

Based on the type, the global viral vector manufacturing market can be segmented into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. Currently, adeno-associated viral vectors hold the majority of the total market share.

Based on the disease, the global viral vector manufacturing market has been divided into cancer, genetic disorders, infectious diseases, and others. Among these, cancer currently exhibits a clear dominance in the market.

Based on the application, the global viral vector manufacturing market can be categorized into gene therapy and vaccinology. Currently, gene therapy accounts for the largest market share.

 

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

 

Some of the major players in the global viral vector manufacturing market include Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and uniQure N.V.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4